Governance
CIRS is governed by its own dedicated advisory boards made up of external international experts from academia, industry, regulatory agencies and HTA bodies.
The Scientific Advisory Council (SAC) and HTA Steering Committee advise CIRS on workshops, special projects, publications as well as the research programme, to ensure neutrality and that the areas are unbiased and the programme meets the needs to all stakeholders. The selection of Committee Members and Chairs is set out in the Terms of Reference of each committee.
| Scientific Advisory Council (SAC) | ||
|---|---|---|
| Chair: Adjunct Prof John Skerritt | Deputy Secretary for Health Products Regulation, Department of Health, Australia | |
| Vice-Chair: Prof Hans-Georg Eichler | Consulting Physician of the Association of Austrian Social Insurance Institutions | |
| Dr Fabio Bisordi | Global Head International Regulatory Policy, F.Hoffman-LaRoche Ltd | |
| Dr Claus Bolte | Head of Sector Marketing Authorisation, Swissmedic | |
| Dr Harald Enzmann | Chair, European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) | |
| Dr Carlos Garner | Vice President, Global Regulatory Affairs, Eli Lilly and Co. | |
| Adrian Griffin | Vice President for HTA Policy, Johnson & Johnson | |
| Dr Ian Hudson | Senior Advisor, Integrated Development, Global Health, Bill and Melinda Gates Foundation | |
| Dr David Jefferys | SVP, Head of Global Regulatory, Eisai Europe Ltd | |
| Prof John Lim | Executive Director of Centre of Regulatory Excellence (CoRE), Duke-NUS Medical School and Chairman, Consortium for Clinical Research & Innovation Singapore | |
| Dr Sabine Luik | Chief Medical Officer and Senior Vice President, Global Medical, Regulatory & Quality, GlaxoSmithKline | |
| Dr Jacques Mascaro | Senior Vice President, Oncology Regulatory Science, Strategy and Excellence, AstraZeneca | |
| Dr Theresa Mullin | Director, Office of Strategic Programs, US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) | |
| Dr Brian O’Rourke | Former CEO and President, Canadian Agency for Drugs and Technologies in Health (CADTH), Canada | |
| Dr Junko Sato | Office Director, Office of International Program, Pharmaceuticals and Medical Devices Agency (PMDA), Japan | |
| Dr Xie Songmei | Deputy Director of Clinical Department Center for Drug Evaluation, National Medical Products Administration (NMPA), China | |
| Jerry Stewart | Vice President, Head of Global Regulatory Policy & Intelligence, Pfizer | |
| Dr John Patrick Stewart | Director General, Therapeutic Products Directorate, Health Canada | |
| Dr Stefan Thirstrup | Chief Medical Officer, EMA | |
| Natalie Tolli | Vice President, Regulatory Affairs (Regulatory International, Regulatory Policy & Intelligence), Abbvie | |
| Prof Stuart Walker | Founder, CIRS | |
| Specialist Advisors | ||
|---|---|---|
| Dr Thomas Lönngren | Former Executive Director, EMA | |
| Dr Murray Lumpkin | Deputy Director, Integrated Development, and Lead for Global Regulatory Systems Initiatives, Bill and Melinda Gates Foundation | |
| Prof Mamoru Narukawa | Professor, Pharmaceutical Medicine, Kitasato University Graduate School of Pharmaceutical Sciences, Japan | |
| Dr Tomas Salmonson | Former Chair, CHMP/EMA | |
| Dr Joseph Scheeren | Former President and CEO, Critical Path Institute | |
| HTA Steering Committee | |
|---|---|
| Chair: Dr Brian O’Rourke | Former CEO and President, CADTH, Canada |
| Vice-Chair: Prof Adrian Towse | Director Emeritus and Senior Research Fellow, Office of Health Economics (OHE) |
| Dr Indranil Bagchi | Senior Vice President and Worldwide Head of Value and Access, Novartis |
| Prof Finn Børlum Kristensen | Former EUnetHTA Executive Committee Chairman and EUnetHTA Secretariat Director, Faculty of Health Sciences, University of Southern Denmark |
| Dr Nick Crabb | Programme Director, Scientific Affairs, National Institute for Health and Care Excellence (NICE) |
| Prof Hans-Georg Eichler | Consulting Physician of the Association of Austrian Social Insurance Institutions |
| Dr Melinda Goodall | Director, Health Technology Assessment Policy Research, Policy Evidence Research, CORE, MSD |
| Dr Wim Goettsch | Associate Professor HTA, Utrecht University and Special Advisor HTA, ZIN, The Netherlands |
| Adrian Griffin | Vice President for HTA Policy, Johnson & Johnson |
| Dr Michael Happich | Director, BioMed HTA, Eli Lilly and Co |
| Dr Adam Heathfield | Senior Director, Patient and Health Impact Innovation Centre, Pfizer |
| Niklas Hedberg | Chief Pharmacist, TLV, Sweden |
| Suzanne McGurn | CEO and President, CADTH, Canada |
| Andrew Mitchell | Strategic Advisor, Department of Health, Australia |
| Dr Detlev Parow | Former Head, Department of Medicines, Medical Remedies and Selective Contracts, DAK – Gesundheit, Germany |
| Dr Vanessa Elisabeth Schaub | Global Access Chapter Lead for Evidence, Roche |
| Dr Sean Tunis | Principal, Rubix Health |